key: cord-0757570-wvka61r5
authors: Lee, Todd C.; Murthy, Srinivas; Del Corpo, Olivier; Senécal, Julien; Butler-Laporte, Guillaume; Sohani, Zahra N.; Brophy, James M.; McDonald, Emily G.
title: Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis
date: 2022-05-19
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.04.018
sha: 6831c07e683303630b38e5171bca0787dd4dee32
doc_id: 757570
cord_uid: wvka61r5

BACKGROUND: The benefits of remdesivir in the treatment of hospitalized patients with Covid-19 remain debated with the National Institutes of Health and the World Health Organization providing contradictory recommendations for and against use. OBJECTIVES: To evaluate the role of remdesivir for hospitalized inpatients as a function of oxygen requirements. DATA SOURCES: Beginning with our prior systematic review, we searched MEDLINE using PubMed from January 15, 2021, through January 22, 2022. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials; all languages. PARTICIPANTS: All hospitalized adults with Covid-19. INTERVENTIONS: Remdesivir, in comparison to either placebo, or standard of care. ASSESSMENT OF RISK OF BIAS: We used the ROB-2 criteria. METHODS OF DATA SYNTHESIS: The primary outcome was mortality, stratified by oxygen use (none, supplemental oxygen without mechanical ventilation, and mechanical ventilation). We conducted a frequentist random effects meta-analysis on the risk ratio (RR) scale and, to contextualize the probabilistic benefits, we also performed a Bayesian random effects meta-analysis on the risk difference scale. A ≥1% absolute risk reduction was considered clinically important. RESULTS: We identified 8 randomized trials, totaling 9157 participants. The RR for mortality comparing remdesivir versus control was 0.71 (95% confidence interval [CI] 0.42-1.22) in the patients who did not require supplemental oxygen; 0.83 (95%CI 0.73-0.95) for nonventilated patients requiring oxygen; and 1.19 (95%CI 0.98-1.44) in the setting of mechanical ventilation. Using neutral priors, the probabilities that remdesivir reduces mortality were 74.7%, 96.9% and 8.9%, respectively. The probability that remdesivir reduced mortality by ≥1% was 88.1% for nonventilated patients requiring oxygen. CONCLUSIONS: Based on this meta-analysis, there is a high probability that remdesivir reduces mortality for nonventilated patients with COVID-19 requiring supplemental oxygen therapy. Treatment guidelines should be re-evaluated.

The World Health Organization (WHO) recommends against the use of remdesivir [1] for all patients with Covid-19, based primarily on the results of the SOLIDARITY trial, which failed to demonstrate a reduction in hospital length of stay or mortality [2] . Likewise, the American College of Physicians has recently concluded that "remdesivir probably results in little to no difference in mortality. [3] " By contrast, guidelines from the National Institutes of Health [4] and the Infectious Diseases Society of America [5] recommend the use of remdesivir in the treatment of Covid-19 for patients who do not require mechanical ventilation. These recommendations follow the completion of the Adaptive Covid-19 Treatment Trial 1 (ACTT-1) [6] , which demonstrated a substantial decrease in hospital length of stay. On an international level, the benefits of remdesivir for the treatment of Covid-19 therefore remain debated and, in many countries, treatment with remdesivir may be underutilized. Indeed, only 20% of moderatesevere Covid-19 patients received remdesivir in a recent randomized controlled trial of baricitinib from the RECOVERY group [7] .

We previously hypothesized that conflicting trial results relate to the differential effects of remdesivir as a function of the severity of the underlying illness. We tested this hypothesis in January 2021, when we conducted a Bayesian meta-analysis to determine the probability that remdesivir reduces mortality as a function of oxygen requirements [8] . Our findings suggested that the probability of any mortality benefit was 69% among patients without oxygen requirements, 92% in those requiring supplemental oxygen who were not ventilated, and only 7% among patients requiring mechanical ventilation. Though not assessed, the certainty of the evidence was low, rated down for imprecision and inconsistency or trial results. Since this time, two large new trials comparing remdesivir versus standard of care have been published [9, 10] .

We therefore conducted a systematic review and meta-analysis to clarify whether remdesivir reduces mortality in hospitalized patients with Covid-19.

We searched PubMed from January 1 st , 2020, to January 21, 2022, to identify randomized controlled trials comparing remdesivir to placebo or standard of care in all hospitalized adults.

There were no language restrictions. Newly identified trials were added to our previous results [8] . We used the search syntax "remdesivir AND (randomized OR randomised) AND 2021-01-J o u r n a l P r e -p r o o f 15[dp]:2022-01-21[dp]". Two independent reviewers screened for eligibility. Studies were included if they recruited hospitalized adult patients and reported either all-cause mortality or provided sufficient data to calculate all-cause mortality. There were no exclusion criteria. During peer review, the search was repeated using the Cochrane Library, which yielded no additional trials.

The primary outcome of interest was mortality, stratified by baseline oxygen support. Two reviewers independently extracted this data. Oxygen support was defined according to categories in the largest trial, SOLIDARITY, as: (i) no oxygen required; (ii) supplemental oxygen (without mechanical ventilation); and (iii) mechanical ventilation.

Two independent reviewers assessed each study for bias using the Cochrane risk-of-bias 2 tool for randomized trials (version 2).

The results are reported according to the PRISMA 2020 checklist [11] . All analysis was stratified by the level of oxygen support. We started with a frequentist analysis, as this is the method understood by most readers and because it provides for a more direct comparison with other systematic reviews of treatments for Covid-19. A Restricted Maximum Likelihood Estimation (REML) random effects meta-analysis on the risk ratio (RR) scale was used to undertake our frequentist analysis using the metan [12] command in STATA version 17 (STATACorp, USA).

During peer review, two sensitivity analyses were conducted. First, we repeated the analysis excluding any trials where we were unable to exactly categorize all patients into the WHO SOLIDARITY oxygen support strata. Second, we repeated the analysis excluding trials at high risk of bias.

Next, to quantify the mortality benefit in absolute terms and to address clinically meaningful differences (a priori defined as the probability of achieving at least a 1% absolute mortality reduction), we conducted a Bayesian meta-analysis on the risk difference scale using R [13] and the bayesmeta package [14] . Vague proper non-informative priors were used: μ centered at 0 (standard deviation = 4), which corresponds to no effect; and heterogeneity τ assumed to be half-normal prior with a scale of 0.03 [8] . Figures of posterior density vs. absolute differences in mortality between remdesivir and control patients were generated, and we integrated the area J o u r n a l P r e -p r o o f under the curve to obtain the probability for any mortality benefit and for a benefit exceeding 1% respectively [8] .

Certainty of evidence for mortality was assessed using the grading of recommendations assessment, development, and evaluation (GRADE) approach [15] . Two reviewers with familiarity and experience with GRADE rated each domain separately; discrepancies were resolved by consensus. Certainty was rated as high, moderate, low, or very low, based on the GRADE domains.

The initial meta-analysis in January 2021 included 4 trials [8] ; the present search yielded an additional 148 articles, of which 5 new trials were reviewed for eligibility for inclusion [9, 10, [16] [17] [18] (Figure 1) . One of the trials only contained patients previously reported in SOLIDARITY and was thus excluded [16] . A total of 8 RCTs were included in the present analysis ( Table 1) .

The trial by Spinner et al. [19] included children ages 12-17 but we were unable to uniquely identify their results. Children are at very low risk of mortality. Nonetheless, as the median age of all groups was 56-58 with IQRs ranged from 45-66, we believe that the data is representative of an adult population.

The DISCOVERY [10] and CATCO [9] trials were previously partially reported as part of the SOLIDARITY trial; therefore, to avoid duplication, we obtained data directly from the study teams on the subset of patients who were not already included in the SOLIDARITY report.

Results of the Mahajan et al. [18] study were not presented as intention-to-treat. We therefore reanalyzed their data using the intention-to-treat principle. We also included participants who were discharged before day 12 (categorized as alive), as well as those who died before day 12 (categorized as deceased). Some trials deviated from the oxygen support categories described in the SOLIDARITY trial. We made the following adjustments to include them in our analyses. For the trial by Wang et al. [20] , although study inclusion criteria required the use of oxygen, 3 patients in the placebo group were not receiving oxygen at the time of their first dose of remdesivir and there was one mechanically ventilated patient in the placebo group. We included all patients in the J o u r n a l P r e -p r o o f 'supplemental oxygen without mechanical ventilation' group. For the trial by Spinner et al. [19] , although oxygen requirement was a study exclusion criterion, 14% and 19% of remdesivir and control patients, respectively, developed a need for supplemental oxygen between screening and the first dose of remdesivir. However, results were not reported by day 1 oxygen requirements. As most patients did not require supplemental oxygen, and due to the overall low mortality rate in both arms, we included this study in the 'no oxygen support' group. Next, the participants in the DISCOVERY trial [10] were classified according to disease severity. Moderate disease severity (no oxygen [16 total patients] and oxygen by nasal prongs or mask) and severe disease (high flow nasal oxygen, non-invasive, and invasive ventilation). We assigned the moderate group (n=223) to 'supplemental oxygen without mechanical ventilation' and the severe group (n=169) to 'mechanical ventilation'. Finally, the trial by Abd-Elsalam et al. [17] included mild and moderate severity patients with an average oxygen saturation of 87% and 89% in the remdesivir and control groups respectively. Although this study did not report results stratified by baseline oxygen requirements, mechanical ventilation was a trial exclusion criterion.

We assigned these patients to the 'supplemental oxygen without mechanical ventilation'

subgroup.

The meta-analysis includes 8 trials (Table 1) [2, 6, 9, 10, [17] [18] [19] [20] comprising 9157 unique patients (2148 without oxygen, 5974 receiving supplemental oxygen without ventilation, and 1035 receiving mechanical ventilation; Figure 2 ). All but 2 studies [17, 18] were considered at overall low risk for bias (Supplemental Figure 1 ). While 6 of 8 studies were not placebo controlled, we believed there was low risk of bias considering the outcome of all-cause mortality.

With respect to the primary outcome of mortality, treatment with remdesivir was associated with a RR and 95% confidence interval (CI) of 0.71 (95%CI 0.42-1.22; I 2 =0.0%) for patients without oxygen; 0.83 (95%CI 0.73-0.95; I 2 =0.0%) for patients requiring oxygen, and 1.19 (95%CI 0.98-1.44; I 2 =0.0%) for those on mechanical ventilation (Figure 2) . The results of the two sensitivity analyses were largely consistent (Supplemental Figures 2 and 3) . On the risk difference scale, for patients without oxygen the probability of any mortality benefit was 74.7%, for those requiring oxygen 96.9%, and for those on mechanical ventilation was 8.9% (Figure 3) . For patients requiring oxygen without the need for mechanical ventilation, the mean estimate for the absolute J o u r n a l P r e -p r o o f risk difference was 2.4% and the probability that the absolute risk reduction was ≥1% was 88.1%.

Regarding the overall certainty of the evidence, the primary outcome of our analysis was mortality, which is not likely subject to adjudication bias. However, most of the included studies were open label, and some evidence suggest that the effect size for mortality might be slightly lower with placebo control [21] . There was also the potential for some misclassification of oxygen requirements, reducing the overall certainty of the evidence away from high. The probability of benefit in the oxygenated subgroup, and correspondingly of harm in the mechanical ventilation subgroup (91.1%), were both high. In these respective subgroups, a recommendation for and against remdesivir is proposed with moderate certainty. It should be noted that participants requiring high flow nasal cannula and non-invasive ventilation were underrepresented in the included trials rendering the certainty of evidence low for this subgroup.

Finally, the suggestion of a mortality benefit in patients who do not require oxygen is also of low certainty, given the probability of a meaningful effect was very modest. The results were also downgraded for inconsistency as there remained a 25.3% probability of increased mortality, and there were very few patients who died in either group.

Our meta-analysis comparing remdesivir versus placebo or standard of care suggests a high probability of a clinically meaningful reduction in mortality for patients requiring supplemental oxygen. Although an analysis of remdesivir trials stratified by oxygen requirements is post hoc, the ACTT-1 trial [6] already suggested a potential mortality benefit for patients in the "Goldilocks zone" (disease severity requiring oxygen without needing critical care). By contrast, we found a high probability that remdesivir harms patients requiring mechanical ventilation and that any beneficial effect size is much smaller for patients who did not require any supplemental oxygen.

There are still unanswered questions related to remdesivir treatment in hospitalized patient subgroups, which could be the focus of future randomized trials. For example, whether there is a benefit in early nosocomial Covid-19, or "incidental" non-hypoxemic Covid-19 for patients at high risk for deterioration. This could be akin to the benefit observed in the recent PINETREE trial that demonstrated superiority of 3 days of remdesivir versus placebo in high risk outpatients [22] . Likewise, the role of remdesivir in the setting of high flow nasal oxygen or non-invasive J o u r n a l P r e -p r o o f ventilation needs to be clarified as, to date, this population is less represented in trials, or the total data is not sufficiently granular.

The strengths of this analysis are the avoidance of duplicated patients despite the inclusion of published SOLIDARITY country-level studies, our a priori decision to stratify the analysis by oxygen requirements, and the consistent and complimentary results of the frequentist and Bayesian analysis. The later allows us to contextualize the probability of a clinically meaningful reduction in mortality from remdesivir in a way that the relative risk does not.

There are limitations to this analysis, the principal one being that the standard of care for Covid-19 continues to evolve at a staggering pace. Earlier in the pandemic, trial participants were less likely to receive treatments now known to reduce adverse outcomes including steroids, monoclonal antibodies, immunomodulatory therapies, or therapeutic anticoagulation.

Additionally, very few of the participants included in this analysis were vaccinated against Covid-19 and all results predate the delta and omicron variants. It is unlikely that there will be additional large randomized controlled trials of remdesivir in vaccinated patients or with newer variants remains and this makes inferences about the magnitude of benefit of remdesivir in these populations challenging. While we feel confident (moderately certain) about the inferences made for patients who require oxygen or mechanical ventilation, it is important to note that there were very few deaths in patients who did not require oxygen. A mortality benefit in this group presumably needs to be better delineated in the context of modern therapy and the baseline risk of the patient. A final limitation we wish to note is a small lack of granularity with respect to oxygen requirements for a handful of patients; however, in our sensitivity analyses which excluded those trials, there were only very small differences in the estimate of relative risk reduction. An individual patient meta-analysis could provide more precise results and transparent data reporting and while data sharing is welcomed, we recognize the complexities of conducting such a multinational study.

There is a high probability (97%) that remdesivir reduces mortality for patients who require oxygen but who are not yet critically ill. Future antiviral treatment trials for noncritically ill hospitalized patients with Covid-19 should likely include remdesivir as an active treatment arm, stratified by oxygen requirements. Importantly, we hope the results of this meta-analysis support harmonization of discrepant international guideline recommendations and facilitate the appropriate uptake of remdesivir in certain patient populations.

The first author named is the lead author and corresponding author. The last author is the senior author. We describe contributions to the paper as follows: 

Not required.

As this was an update of previous work based on newly published information, this systematic review was not pre-registered, and a specific protocol was not prepared.

All data required to replicate this analysis is included in the manuscript. Statistical code is available for audit upon written request.

J o u r n a l P r e -p r o o f Eligible patients were men and non-pregnant women with COVID-19 who were aged at least 18 years and were RT-PCR positive for SARS-CoV-2, had pneumonia confirmed by chest imaging, had oxygen saturation of 94% or lower on room air or a ratio of arterial oxy-gen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and were within 12 days of symptom onset.

Exclusion: pregnancy or breast feeding; cirrhosis; ALT or AST >5 times limit of normal; eGFR<30; dialysis; possibility of transfer to a non-study hospital ≤72h.

Eligible patients were randomly assigned (2:1) to either the remdesivir (10d) group or the placebo group.

Remdesivir: 158 Control: 79 (1 withdrew consent)

Time to clinical

Division of General Internal Medicine

A living WHO guideline on drugs for covid-19

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Metaanalysis for the American College of Physicians Practice Points

COVID-19) Treatment Guidelines. National Institutes of Health

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Remdesivir for the Treatment of Covid-19 -Final Report

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label

Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis

Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Metan: Fixedand Random-Effects Meta-Analysis

R: A language and environment for statistical computing. R Foundation for Statistical Computing

Bayesian Random-Effects Meta-Analysis Using the bayesmeta R Package

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19

Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial

Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Association Between Lack of Blinding and Mortality Results in Critical Care Randomized Controlled Trials: A Meta-Epidemiological Study

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

The authors wish to thank all the DISCOVERY trial team and the CATCO team for providing the unpublished data required to complete this analysis.J o u r n a l P r e -p r o o f